Introduction
============

Aspirin is easily available across the counter in most countries including the developing countries such as Nigeria. When indicated, it is a common practice to maintain patients on long-term, low dose aspirin use without assessing their renal status prior to initiation of treatment.

Low dose aspirin is increasingly being used as an antiplatelet to prevent thrombosis and other fatal cardiovascular outcomes in at-risk patients.[@b1-ijgm-6-019],[@b2-ijgm-6-019] Elderly patients not only form the majority of these at-risk patients,[@b1-ijgm-6-019],[@b2-ijgm-6-019] but they also readily succumb to the deleterious effects of aspirin on renal function.[@b3-ijgm-6-019]--[@b5-ijgm-6-019]

Various studies assessing the elderly among Caucasian populations have shown that 1--2 weeks of low dose aspirin use (75 mg--325 mg/day) caused significant decreases in both creatinine clearance (CrCl) and uric acid clearance, as well as elevations in serum creatinine and uric acid.[@b6-ijgm-6-019]--[@b8-ijgm-6-019] These parameters improved upon withdrawal of the drug, but the decline in the glomerular filtration rate persisted 3 weeks posttreatment.[@b6-ijgm-6-019]--[@b8-ijgm-6-019] Thus, long-term aspirin administration may have clinically important deleterious effects on renal function.[@b8-ijgm-6-019]

This study was therefore undertaken as a pilot study to ascertain whether low dose aspirin compromises renal function amongst Nigerians, and if so, to alert practicing physicians on the need to show discretion when prescribing this drug.

Methods
=======

This study employed a cohort of 30 elderly patients (age ≥ 60 years) from the Ladoke Akintola University of Technology Teaching Hospital, southwest Nigeria, and was comprised of 16 male and 14 female patients at the commencement of the study. The United Nations definition of an elderly person was used.[@b9-ijgm-6-019] Ladoke Akintola University of Technology Teaching Hospital ethical clearance was obtained, and all of the patients gave informed consent (verbal and written). The patients were those enrolled in long-term care, as well as new patients with various medical conditions necessitating the use of low dose aspirin that were in stable clinical conditions throughout the study. Each patient was followed up for a period of 6 weeks with a weekly clinic appointment.

Excluded from the study were patients with a history of active peptic ulcer, gastrointestinal bleeding, chronic liver diseases, hyperuricemia, serum creatinine \> 1.5 mg/dL (132.6 μmol/L), a significant history of alcohol consumption, or recent use of anticoagulants, aspirin, or nonsteroidal anti-inflammatory drugs. Patients were put on moderate protein intake (0.6--0.8/kg of body weight) with the assistance of dieticians a week prior to the commencement of the study; this was maintained throughout the 6-week study. The status quo was maintained for all other drugs (dosages unchanged), including diuretics. Patients who dropped out of the study were included in the calculations until their exit. The study took place over a period of 12 months from January 2008 to December 2008.

Blood and 24-hour urine were collected before the first dose of aspirin. Aspirin at a dose of 75 mg/day was administered orally after breakfast for 2 weeks and then stopped. Follow-up then continued for a further 4 weeks.

Blood and 24-hour urine were collected at the end of each treatment week, as well as after each of the four consecutive weeks follow-up visits. Subjects were taught how to collect their 24-hour urine prior to their clinic day when the blood would be collected. After an overnight fast, 10 mL of venous blood was collected at the ante cubital fossa in the sitting position without stasis; 5 mL of the blood was put into lithium heparinized bottle, and the remaining 5 mL were put into a plain bottle. Serum was obtained after clotting, centrifuged at 3500 rpm for 10 minutes, and immediately stored at −20°C until they were analyzed. Sodium and potassium were analyzed using flame emission photometry (Corning 410c photometer CIBA Corning Analytical, Halstead Essex, UK), bicarbonate by method of back titration, and chloride by rapid precision method.[@b10-ijgm-6-019]

Serum creatinine, blood urea nitrogen, uric acid, and albumin were analyzed by standard methods of Jaffes reaction,[@b11-ijgm-6-019] modified Berthelot,[@b12-ijgm-6-019] enzymatic urease,[@b13-ijgm-6-019] and bromocresol green,[@b14-ijgm-6-019] respectively, using the Humalyzer 2000 Chemistry Analyzer (HUMAN Gesellschaft für Biochemica und Diagnostica mbH, Wiesbaden, Germany). Urinary CrCl and uric acid clearance were evaluated by 24-hour urine collection for CrCl and uric acid clearances.

The small sample size is a limitation of this study.

Statistics
----------

Pro forma data entry and statistical analysis were performed. Each patient's baseline samples at enrolment (before commencing aspirin) served as the control, and subsequent weekly samples were compared. The weekly mean of the samples was calculated, and the difference of means from the baseline mean were determined and compared for statistical significance (*P* ≤ 0.05) using the Statistical Package for the Social Sciences version 16 software (SPSS Inc, Chicago, IL, USA).

Results
=======

A total of 30 black Nigerians participated in this preliminary study. There were 14 (46.7%) females and 16 (53.3%) males with age range between 60--88 years and mean ages of 68.44 years (±8.16) and 70.43 years (±9.09) for males and females, respectively.

[Table 1](#t1-ijgm-6-019){ref-type="table"} shows the clinical data of the patients. Twelve (40%) of the patients had more than one diagnosis. Systemic hypertension was the most common diagnosis, accounting for 18 (60.0%) of cases. Hypertension and diabetes mellitus coexisted in seven (23.3%) of the study participants.

[Table 2](#t2-ijgm-6-019){ref-type="table"} shows the stages of renal function based on the National Kidney Function/DOQI guideline: 86.67% exhibited their basal renal function in stages 1 and 2 based on CrCl.

[Figures 1](#f1-ijgm-6-019){ref-type="fig"}--[8](#f8-ijgm-6-019){ref-type="fig"} show the weekly assessment of the effects of low dose aspirin on renal functions among the patients in graphical form. The mean of each weekly parameter was compared with the corresponding baseline parameter, as well as with the *P*-value displayed on the graph. The *P*-value for all these weekly parameters did not show statistical significance except for the CrCl ([Figure 8](#f8-ijgm-6-019){ref-type="fig"}; *P* = 0.025). The CrCl reduced at week 2, and then increased at week 3, pleateauing before gradually returning to baseline at the sixth week.

The mean hemoglobin was 12.3 ± 5.6 g/dL with a range of 7.3--15.0 g/dL.

Discussion
==========

This study did not show any significant deterioration effects in renal function in the geriatric patients studied, during or after a 2-week administration of low dose (75 mg) aspirin in all of the investigated parameters, as shown in [Figures 1](#f1-ijgm-6-019){ref-type="fig"}--[8](#f8-ijgm-6-019){ref-type="fig"}. This is not in accordance with previously published studies that were conducted outside Nigeria.[@b3-ijgm-6-019],[@b6-ijgm-6-019]--[@b8-ijgm-6-019]

Previous studies have shown that low dose aspirin (75--325 mg) in the elderly, even on a short-term basis, had significant effects on renal tubular function.[@b6-ijgm-6-019]--[@b8-ijgm-6-019] Furthermore, one of the studies showed that even at the lowest dose of aspirin (75 mg) per day, administered for 1 week, the uric acid clearance and CrCl reduced. Only the uric acid clearance returned to the baseline 1 week after the discontinuation of aspirin.[@b6-ijgm-6-019]

The disparity from previous studies noticed in this study may be due to the better baseline renal functions of our patients.

As shown in [Table 2](#t2-ijgm-6-019){ref-type="table"}, more than 85% of the study subjects had their basal renal function (CrCl, 86.7%) in stages 1 and 2 of the American National Kidney Foundation criteria, whereas only about 50% (CrCl, 57%) of the patients in the Segal et al[@b8-ijgm-6-019] study had theirs in the later stages.

Similarly, the study subjects were younger (age range, 60--88 years; overall mean of 69.40 ± 8.48 years) with only four (13.33%) that were considered to be in the very elderly age group (≥80 years). Previous studies used older patients with a mean age of 80 ± 9 years,[@b8-ijgm-6-019] and an average age of 81 years.[@b7-ijgm-6-019] Of note, renal functions depreciate with age;[@b15-ijgm-6-019],[@b16-ijgm-6-019] hence, the basal renal functions of the patients in this study were better than those of other studies. This might have attenuated the renal effects of low dose aspirin.

Only two (6.67%) of the patients in this study were anemic. This is in keeping with the stage of their renal functions. Anemia in chronic kidney disease becomes progressively pronounced from stage 3 onward.[@b17-ijgm-6-019] Similarly, only 14 (46.7%) of the patients had hypoalbuminemia.

Previous studies have shown that hypoalbuminemia and anemia potentiate the deleterious effects of low dose aspirin on renal function.[@b6-ijgm-6-019],[@b8-ijgm-6-019] This current study did not conform to this. This may be due to the very small number of our study patients having either hypoalbuminemia or anemia.

Previous studies have also shown significantly lower CrCl on a concomitant low dose aspirin--diuretic combination.[@b18-ijgm-6-019],[@b19-ijgm-6-019] Our finding differs from this observation, as 93.3% of the patients in this study were on this combination, yet there was no significant lowering of the CrCl. Instead, in [Figure 8](#f8-ijgm-6-019){ref-type="fig"} we observed positive statistical significance (*P* = 0.025) in the CrCl parameter. The CrCl at week 2 reduced and increased by the third week, plateauing before gradually returning to baseline at the sixth week. We are of the opinion that the multiple drugs aimed at ameliorating the various comorbid conditions in the patients of our study might have acted in synergy with the low dose aspirin to give this favorable increase in CrCl during the study. A larger sample with the application of more advanced statistics is advocated in order to provide a more concrete explanation for this observation. The small sample size is a limitation of this study.

The decision to put an elderly patient on low dose aspirin should be based on the basal renal functions and the age of the patient. Caution should be exercised when dealing with those in renal stages 3--5, and when dealing with the very elderly (age ≥ 80 years). We also suggest that the 75 mg dose of aspirin should be retained as the antiplatelet of choice in the elderly in developing countries.

Conclusion
==========

This study did not show any deleterious effects of short-term, low dose aspirin (75 mg) use on the renal function of elderly patients. This 6-week study was cumbersome for most of the patients, and this precluded the participation of a lot of eligible geriatric patients. Not all of the 30 patients completed the study, but their data for the period of participation were included in the analysis.

The small sample size combined with the tasking nature of the study that was conducted in a peculiar setting might have affected the results. We suggest that more studies be conducted in our own environment with a larger sample size, and possibly in a center with a predominant geriatric population.
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###### 

Clinical data

                                                                     Number of patients   \%
  ------------------------------------------------------------------ -------------------- ------
  **Diagnosis**[\*](#tfn2-ijgm-6-019){ref-type="table-fn"}                                
  Systemic hypertension                                              18                   60.0
  Congestive cardiac failure                                         3                    10.0
  Diabetes mellitus                                                  6                    20.0
  Peripheral artery disease                                          5                    16.7
  Carotid aneurysm                                                   1                    3.3
  Ischemic cardiovascular disease                                    2                    6.7
  Obesity                                                            2                    6.7
  Parkinson's disease                                                1                    3.3
  Background COPD                                                    3                    10
  **Drugs**[\*\*](#tfn3-ijgm-6-019){ref-type="table-fn"}                                  
  Diuretics                                                          28                   93.3
  Antibenign prostatic hypertrophy (and receptor blocker)            1                    3.3
  Antihypertensives                                                                       
  Excluding thiazides and angiotensin converting enzyme inhibitors   17                   56.7
  Digoxin                                                            2                    6.7
  Oral hypoglycemic agents                                           5                    16.7
  Insulin                                                            2                    6.7
  Angiotensin converting enzyme inhibitors                           12                   40.0

**Notes:**

Some patients had multiple diagnoses;

all the patients were on multiple drugs.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

NKF/DOQI classification of patients in this study

  Stage   GFR (mL/min)   CrCl (%)
  ------- -------------- -----------
  1       ≥90            17 (56.7)
  2       60--89         9 (30.0)
  3       30--59         4 (13.3)
  4       15--29         --
  5       \<15           --

**Abbreviations:** NKF, National Kidney Foundation; DOQI, Dialysis Outcome Quality Initiative; GFR, glomerular filtration rate; CrCl, creatinine clearance.
